Aug 1 (Reuters) - Immutep Ltd (IMM) :
- IMMUTEP REPORTS NEW POSITIVE INTERIM DATA FROM ITS PHASE II STUDY OF LAG-3 CANDIDATE, EFTILAGIMOD ALPHA, IN 2ND LINE PD-X REFRACTORY NSCLC
- IMMUTEP LTD - CHEMO-FREE THERAPY OF EFTI IN COMBINATION WITH PEMBROLIZUMAB CONTINUES TO BE SAFE AND WELL TOLERATED
News: IMM Immutep Reports New Positive Interim Data From Its Phase II Study Of Lag-3 Candidate,...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
24.5¢ |
Change
-0.005(2.00%) |
Mkt cap ! $359.6M | |||
| Open | High | Low | Value | Volume |
| 25.0¢ | 25.0¢ | 24.3¢ | $239.9K | 976.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1678 | 24.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.0¢ | 138979 | 4 |
View Market Depth
| Last trade - 16.10pm 17/09/2025 (20 minute delay) ? |
| IMM (ASX) Chart |